Drug intelligence / Profile preview

QPexin

Development stage: Unknown
Lead developer: Shionogi

Overview

QPexin is a clinical-stage antibiotic that was originally developed by QPeX Biopharma and subsequently acquired by Shionogi. It is currently in Phase 3 development for the treatment of multidrug-resistant Gram-negative infections, addressing the critical need for new treatments against antimicrobial resistance (AMR).

Beyond the preview

Go deeper on QPexin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QPexin.

Explore the full profile